CRISPR Therapeutics and ViaCyte announce strategic collaboration for diabetes
CRISPR Therapeutics and ViaCyte announced a collaboration focused on discovery, development, and commercialization of gene-edited allogeneic stem cell therapies for treatment of diabetes. ViaCyte will receive $15 million from CRISPR, which may be paid in either cash or CRISPR stock. September 18, 2018